Eisai Deepens Body of Clinical Evidence for LENVIMA (Lenvatinib) Across Established Indications at ASCO 2026

Real-World Evidence to be Presented Comparing First-Line Lenvatinib Versus Dabrafenib Plus Trametinib in BRAF-Mutated Differentiated Thyroid Cancer Additional Analysis from the Pivotal Phase 3 CLEAR Trial Examines Efficacy Outcomes by Patterns of Progression in Advanced Renal Cell...